XTL Biopharmaceuticals has shuttered the development program for XTL-2125 after it failed to demonstrate efficacy in a Phase I trial for hepatitis C. Viral load reductions proved negligible in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback